Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 137,087 | 358,593 | 341,768 | 543,339 | 388,164 |
| Marketable Securities | 291,880 | 98,257 | 149,863 | 231,115 | 191,320 |
| Other current assets | 6,445 | 7,837 | 0 | 9,675 | 7,264 |
| TOTAL | $435,412 | $464,687 | $502,320 | $784,129 | $586,748 |
| Non-Current Assets | |||||
| PPE Net | 208,412 | 185,724 | 154,913 | 126,525 | 105,690 |
| Investments And Advances | 10,046 | 10,007 | 13,362 | 13,313 | 0 |
| Intangibles | 31,135 | 31,723 | 32,311 | 0 | 0 |
| Other Non-Current Assets | 36,804 | 37,911 | 39,124 | 39,490 | 33,107 |
| TOTAL | $286,397 | $265,365 | $239,710 | $179,328 | $138,797 |
| Total Assets | $721,809 | $730,052 | $742,030 | $963,457 | $725,545 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 502 | 492 | 483 |
| Accounts payable and accrued liabilities | 5,998 | 5,204 | 3,644 | 6,914 | 6,354 |
| Accrued Expenses | 10,813 | 8,518 | 10,903 | 7,950 | 8,120 |
| Other current liabilities | 1,089 | 1,163 | N/A | N/A | N/A |
| TOTAL | $30,452 | $33,751 | $35,072 | $33,791 | $26,159 |
| Non-Current Liabilities | |||||
| Long Term Debt | 7,903 | 8,196 | 8,523 | 8,801 | 9,070 |
| Deferred Revenues | N/A | N/A | 161 | 374 | N/A |
| Other Non-Current Liabilities | 250,000 | 250,000 | 250,104 | 400,000 | 150,000 |
| TOTAL | $257,903 | $258,196 | $258,627 | $408,862 | $159,145 |
| Total Liabilities | $288,355 | $291,947 | $293,699 | $442,653 | $185,304 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 95,122 | 94,141 | 93,936 | 93,724 | 93,659 |
| Common Shares | 951 | 941 | 939 | 937 | 937 |
| Retained earnings | -245,361 | -232,909 | -220,291 | -147,430 | -128,555 |
| Other shareholders' equity | -1,377 | 745 | 890 | 2,184 | 3,189 |
| TOTAL | $433,454 | $438,105 | $448,331 | $520,804 | $540,241 |
| Total Liabilities And Equity | $721,809 | $730,052 | $742,030 | $963,457 | $725,545 |